by Green Griffith | Aug 7, 2018 | IP News
The Federal Circuit, in its July 9, 2018, decision Applications In Internet Time (AIT) v. RPX Corp. (Appeal Nos. 2017-1698, -1699 & -1701), states that PTAB used an “unduly restrictive test” for determining whether a person is a “real party in interest” under 35...
by Green Griffith | Aug 3, 2018 | IP News
FDA will accept public comments at its White Oaks Headquarters on September 4, 2018, on 9 questions, including whether biologics should receive exclusivities, and the ability to use label carve-outs, similar to the treatment afforded small molecules. As part of its...
by Green Griffith | Jul 25, 2018 | Firm News, IP News
Green, Griffith & Borg-Breen continues to expand its experienced IP team with the addition of Timothy O’Brien. Green Griffith is pleased to announce the addition of Timothy O’Brien to its Intellectual Property team as an Associate Attorney. Tim graduated with...
by Green Griffith | Jul 24, 2018 | IP News
On July 18, 2018, FDA released an 11-point plan of action which it contends will “encourage innovation and competition among biologics and the development of biosimilars.” Since passage of the Biologics Price Competition and Innovation Act (“BPCIA”) in 2010, FDA has...
by Green Griffith | Jun 26, 2018 | Firm News, IP News
Green Griffith successfully defended one of Horizon’s Orange Book-listed patents (U.S. 8,642,012) for its RAVICTI® oral liquid product at the Federal Circuit against Par Pharmaceutical’s appeal of an unsuccessful inter partes review (“IPR”) proceeding. In a decisive...
by Green Griffith | May 22, 2018 | IP News
The Patent Trial and Appeal Board (PTAB) issued a guidance document addressing the impact of the SAS Decision on Inter Partes Reviews. The PTAB’s guidance document outlines new procedures that will be followed in an Inter Partes Review (IPR) as a result of the U.S....
